Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy.
Journal Article (Journal Article)
The translation of fundamental science-based constructs to the preemptive identification and optimal management of individuals with or those at risk for thrombotic disorders of the cardiovascular system has taken a step closer to being realized with the development of molecular technologies that include nucleic acid aptamers and their complimentary oligonucleotide antidotes. Herein, we summarize our experience with factor IX and von Willebrand factor aptamers, and introduce the era of antithrombotic pharmacobiologic therapy.
Full Text
Duke Authors
Cited Authors
- Becker, RC; Oney, S; Becker, KCD; Rusconi, CP; Sullenger, B
Published Date
- December 2007
Published In
Volume / Issue
- 27 / 5
Start / End Page
- 378 - 382
PubMed ID
- 18060250
International Standard Serial Number (ISSN)
- 0720-9355
Language
- eng
Conference Location
- Germany